These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28697319)

  • 1. Renal Medullary Carcinoma: Establishing Standards in Practice.
    Beckermann KE; Sharma D; Chaturvedi S; Msaouel P; Abboud MR; Allory Y; Bourdeaut F; Calderaro J; de Cubas AA; Derebail VK; Hong AL; Naik RP; Malouf GG; Mullen EA; Reuter VE; Roberts CWM; Walker CL; Wood CG; DeBaun MR; Van Poppel H; Tannir NM; Rathmell WK
    J Oncol Pract; 2017 Jul; 13(7):414-421. PubMed ID: 28697319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Medullary Carcinoma: a Report of the Current Literature.
    Blas L; Roberti J; Petroni J; Reniero L; Cicora F
    Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is renal medullary carcinoma the seventh nephropathy in sickle cell disease? A multi-center Nigerian survey.
    Anazoeze M; Najibah G; Garba U; Shehu A; Florence F; Abdulaziz H; Marcus I; Oluwaseun A; Theresa N; Obike I; Sunday O; Ifeoma E; Anthony I; Barth C; Chide O; Joseph O; Malachy I; Kaladada K; Uche A; Kingsley A; Charles N; Angela U; Augustin D; Chikwudi A; Alozie E; Uchenna O; Caroline O; Obineche A; Iheanyi O
    Afr Health Sci; 2016 Jun; 16(2):490-6. PubMed ID: 27605964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
    Msaouel P; Tannir NM; Walker CL
    Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
    J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.
    Lebenthal JM; Kontoyiannis PD; Hahn AW; Lim ZD; Rao P; Cheng JP; Chan B; Daw NC; Sheth RA; Karam JA; Tang C; Tannir NM; Msaouel P
    Eur Urol Oncol; 2024 Jul; ():. PubMed ID: 39013742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Renal Medullary Carcinoma.
    Su Y; Hong AL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
    Carter SA; Walker AN
    J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
    Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
    BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
    Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
    Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases.
    Miller DL; Ribeiro EA; Roy-Chowdhuri S; Illei PB; Siddiqui MT; Ali SZ
    J Am Soc Cytopathol; 2021; 10(2):187-196. PubMed ID: 32651128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Lai JZ; Lai HH; Cao D
    Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal medullary carcinoma: A national analysis of 159 patients.
    Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal medullary carcinoma: the Bronx experience.
    Hakimi AA; Koi PT; Milhoua PM; Blitman NM; Li M; Hugec V; Dutcher JP; Ghavamian R
    Urology; 2007 Nov; 70(5):878-82. PubMed ID: 18068443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.